Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 1.6% – Should You Sell?

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) traded down 1.6% on Thursday . The company traded as low as $9.41 and last traded at $9.84. 354,980 shares changed hands during trading, a decline of 75% from the average session volume of 1,403,603 shares. The stock had previously closed at $10.00.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on Tonix Pharmaceuticals in a report on Monday, February 10th. They set a “sell” rating on the stock.

Tonix Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The firm has a market capitalization of $17.15 million, a price-to-earnings ratio of 0.00 and a beta of 2.07. The business has a fifty day moving average of $27.92 and a two-hundred day moving average of $23.43.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. PFG Investments LLC bought a new stake in shares of Tonix Pharmaceuticals during the 4th quarter valued at $72,000. Commonwealth Equity Services LLC bought a new stake in shares of Tonix Pharmaceuticals during the 4th quarter valued at $40,000. Geode Capital Management LLC lifted its position in shares of Tonix Pharmaceuticals by 1,600.1% during the 4th quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company’s stock valued at $650,000 after acquiring an additional 1,855,907 shares during the period. Northern Trust Corp bought a new stake in shares of Tonix Pharmaceuticals during the 4th quarter valued at $162,000. Finally, Jane Street Group LLC lifted its position in shares of Tonix Pharmaceuticals by 5,932.3% during the 4th quarter. Jane Street Group LLC now owns 1,662,682 shares of the company’s stock valued at $548,000 after acquiring an additional 1,635,119 shares during the period. 82.26% of the stock is owned by institutional investors and hedge funds.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.